<DOC>
	<DOCNO>NCT01677377</DOCNO>
	<brief_summary>Evaluate safety tolerability multiple subcutaneous injection various dosage risperidone clinically stable schizophrenia</brief_summary>
	<brief_title>Multiple Ascending Dose Study Safety , Tolerability , Pharmacokinetic/Efficacy</brief_title>
	<detailed_description>This open-label , Phase 2A , multiple ascend dose study 1 3 site , design evaluate safety , tolerability , PK profile multiple subcutaneous injection 60mg , 90mg , 120mg dos risperidone RBP-7000 formulation , subject clinically-stable schizophrenia daily stable dose 2mg , 3mg , 4mg oral risperidone</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Male female &gt; 18 &lt; 65 year Diagnosis paranoid , residual , undifferentiated schizophrenia define DSMIVTR criterion Status : clinically stable subject define subject hospitalization acute exacerbation within 3 month screen screen total PANSS score &lt; 60 Subjects give write informed consent Subjects take risperidone sustain release formulation within 60 day prior study screen Subjects take follow concurrent medication/overthecounter product : Inducers inhibitor CYP2DD6 within 14 day 7 half life ( whichever occurs last ) prior study screen Bupropion , chlorpheniramine , cimetidine , clomipramine , doxepin , quinidine within 30 day prior study screen Clozapine , phenothiazine , aripiprazole , haloperidol , antipsychotic oral risperidone within 14 day prior study screen Selective serotonin reuptake inhibitor ( e.g. , fluoxetine , paroxetine ) serotoninnorepinephrine reuptake inhibitor ( e.g. , venlafaxine , desvenlafaxine , duloxetine ) within 30 day prior study screen Opioids opioidcontaining analgesic within 14 day prior study screen Medications , addition list , may expect significantly interfere metabolism excretion risperidone and/or 9hydroxyrisperidone , may associate significant drug interaction risperidone , may pose significant risk subject ' participation study Subjects history cancer ( exception resect basal cell squamous cell carcinoma skin ) unless disease free &gt; 5 year Subjects another active medical condition organ disease may either compromise subject safety and/or outcome evaluation study drug Subjects evidence history significant hepatic disorder may either compromise subject safety interfere safety and/or outcome evaluation study drug . Individuals acute hepatitis ( include limit B C ) ; individual 1 ) total bilirubin &gt; 1.5x upper limit oof normal and/or 2 ) alanine aminotransferase aspartate aminotransferase &gt; 2x upper limit normal excluded Subjects hepatitis C antibody AST , ALT , alkaline phosphatase &gt; 2x total bilirubin &gt; 1.3 mg/dL exclude Subjects history renal disease , creatinine clearance le 80 mL/min ( determine Cockcroft Gault formula ) Subjects international normalized ratio &gt; 2.0 screen Subjects correct QT interval ( Bazett 's QTcB ) &gt; 450 msec ( male ) &gt; 470 msec ( female ) screen . Subjects QTc level due benign right bundle branch block include study discretion PI Subjects know AIDS HIV positive Subjects suicidal ideation intent plan ( CSSRS affirmative answer question 4 5 ideation section ) suicide attempt within last six month note CSSRS , subject uncontrolled depression opinion investigator Subjects know diagnosis type 1 2 diabetes subject Hemoglobin A1c &gt; 7.0 screen Subjects participate clinical trial within 30 day prior study screen Subjects meet DSMIVTR criterion alcohol abuse dependence within last six month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizophrenic</keyword>
	<keyword>Schizophrenias</keyword>
</DOC>